Clinical TrialJun 1, 2026, 09:03 AM
Alpha Tau Alpha DaRT shows strong survival in pancreatic cancer studies
AI Summary
Alpha Tau Medical announced strong overall survival and safety results from a pooled analysis of three Phase I/II clinical studies for its Alpha DaRT® therapy in pancreatic cancer, presented at the 2026 ASCO Annual Meeting. Patients treated with Alpha DaRT after one prior line of chemotherapy showed median overall survival of 11.2 months in metastatic disease and 11.1 months in locally advanced disease, significantly exceeding historical data. The therapy demonstrated a favorable safety profile with no treatment-related deaths and all Grade ">= 3 adverse events resolving. The company is now focused on completing recruitment for its U.S. IMPACT pancreatic cancer trial.
Key Highlights
- Alpha DaRT achieved median overall survival (mOS) of 11.2 months in metastatic PDAC patients after 1st line chemotherapy.
- Alpha DaRT achieved mOS of 11.1 months in locally advanced PDAC patients after 1st line chemotherapy.
- Alpha DaRT achieved mOS of 7.9 months in metastatic PDAC patients after 2nd line chemotherapy.
- Alpha DaRT achieved mOS of 8.8 months in locally advanced PDAC patients after 2nd line chemotherapy.
- Treatment-associated adverse events were observed in 36% of subjects across studies.
- Grade ">= 3 adverse events occurred in 9% of subjects, with no treatment-related deaths and all resolved.
- Chemotherapy-naive patients demonstrated mOS of 7.1 months from diagnosis in both disease stages.
- Company expects to complete recruitment for the multicenter U.S. IMPACT pancreatic cancer trial.
Price Impact
More from DRTS